• Markets
    • icon
  • Companies
IMU · ASX

Imugene Ltd (ASX:IMU)

AU$0.11

 0.005 (4.762%)
ASX:Live
30/11/2023 04:10:33 PM
Volume Spike (Realtime) Short Sold >1 over the month HALO Small HALO Price Momentum HALO Ords +8
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

IMU Overview

IMU Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About IMU

Website

Imugene Ltd

Telephone

61.3.9824.5254

Address

Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053

Description

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.

IMU Price Chart

Key Stats

Market Cap

AU$716.50M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.04 - 0.2

Trade Value (12mth)

AU$624,383.00

1 week

25%

1 month

150%

YTD

-27.59%

1 year

-43.24%

All time high

0.625

Key Fundamentals

EPS 3 yr Growth

130.800%

EBITDA Margin

N/A

Operating Cashflow

-$30m

Free Cash Flow Return

-18.10%

ROIC

-23.00%

Interest Coverage

-1,788.10

Quick Ratio

27.20

Other Data

Shares on Issue (Fully Dilluted)

6423m

HALO Sector

Healthcare

Next Company Report Date

30-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

6.96

IMU Announcements

Latest Announcements

Date Announcements

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 23

Amended Annual Report

×

Amended Annual Report

31 October 22

First patient dosed in VAXINIA intratumoral cohort 2

×

First patient dosed in VAXINIA intratumoral cohort 2

31 October 22

Imugene Limited - First patient dosed in VAXINIA intratumoral cohort 2 (IMU-AU)

×

Imugene Limited - First patient dosed in VAXINIA intratumoral cohort 2 (IMU-AU)

31 May 22

IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022

×

IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022

31 May 22

Imugene Limited - IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022 (IMU-AU)

×

Imugene Limited - IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022 (IMU-AU)

31 January 22

Oncolytic Virotherapy CF33 Patent Granted in Japan

×

Oncolytic Virotherapy CF33 Patent Granted in Japan

31 January 22

Issue of Options under the Employee Share Option Plan

×

Issue of Options under the Employee Share Option Plan

31 January 22

Imugene Limited - Oncolytic Virotherapy CF33 Patent Granted in Japan (IMU-AU)

×

Imugene Limited - Oncolytic Virotherapy CF33 Patent Granted in Japan (IMU-AU)

31 January 22

Imugene Limited - Issue of Options under the Employee Share Option Plan (IMU-AU)

×

Imugene Limited - Issue of Options under the Employee Share Option Plan (IMU-AU)

31 August 22

Annual Report and Appendix 4E

×

Annual Report and Appendix 4E

31 August 22

Appendix 4G

×

Appendix 4G

31 August 22

Corporate Governance Statement

×

Corporate Governance Statement

31 August 22

Environmental Social and Governance (ESG) Report

×

Environmental Social and Governance (ESG) Report

31 August 22

Imugene Limited - Annual Report and Appendix 4E (IMU-AU)

×

Imugene Limited - Annual Report and Appendix 4E (IMU-AU)

31 August 22

Imugene Limited - Appendix 4G (IMU-AU)

×

Imugene Limited - Appendix 4G (IMU-AU)

31 August 22

Imugene Limited - Corporate Governance Statement (IMU-AU)

×

Imugene Limited - Corporate Governance Statement (IMU-AU)

31 August 22

Imugene Limited - Environmental Social and Governance (ESG) Report (IMU-AU)

×

Imugene Limited - Environmental Social and Governance (ESG) Report (IMU-AU)

31 August 20

Appendix 4E & Annual Report to shareholders

×

Appendix 4E & Annual Report to shareholders

31 August 20

Imugene Limited - Appendix 4E & Annual Report to shareholders (IMU-AU)

×

Imugene Limited - Appendix 4E & Annual Report to shareholders (IMU-AU)

31 August 17

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

31 August 15

Appendix 4E and Annual Report 2015

×

Appendix 4E and Annual Report 2015

30 September 16

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

30 October 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

30 November 23

AGM Presentation

×

AGM Presentation

30 November 23

Results of Meeting

×

Results of Meeting

30 November 12

CTO Presentation

×

CTO Presentation

IMU Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -53.8 -67.5 10.4 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.0 -108.8 -4.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock -0.8 -3.0 0.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.02 0.03 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.02 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.5 197.8 37.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 4,664 5,637 6,276 Lock Lock Lock
Basic m Lock Lock Lock Lock 4,664 5,637 6,276 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 24 48 49 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -2,278.8 -22.7 8.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -24 -48 -49 Lock Lock Lock
     Growth % Lock Lock Lock Lock -60.2 -103.6 -1.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -26 -51 -51 Lock Lock Lock
     Growth % Lock Lock Lock Lock -72.5 -97.4 -1.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -26 -50 -50 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -7 -13 -12 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -18 -38 -38 Lock Lock Lock
     Growth % Lock Lock Lock Lock -75.6 -105.2 -0.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -13 -31 -30 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 5 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -5 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 18 101 83 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -13 -31 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.9 -133.1 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 29 100 153 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 72 148 197 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -29 -99 -153 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 7 9 7 Lock Lock Lock
Equity $m Lock Lock Lock Lock 65 139 190 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 65 139 190 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.0 113.5 36.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -25.7 -25.7 -19.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -28.4 -27.3 -20.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -41.0 -49.5 -31.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -29.5 -37.1 -23.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -21.0 -30.0 -18.1 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -4,718.1 -3,554.2 -1,788.1 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.2 2.1 3.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -44.9 -71.5 -80.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 8.1 15.3 27.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.1 15.3 27.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 81.2 87.8 92.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -294.6 -413.1 -489.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -25.7 -25.7 -19.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -28.4 -27.3 -20.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -28.4 -27.3 -20.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 164.9 399.8 567.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -164.9 -399.8 -567.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

6.96%

Value ($M)

41

Prior Change

-1.00%

7 Day Change

-0.20%

1 Month Change

2.10%

3 Month Change

2.50%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IMU Shortsell

Frequently Asked Questions

The current share price of Imugene Ltd (IMU:ASX) is AU$0.11.
The 52-week high share price for Imugene Ltd (IMU:ASX) is AU$0.20.
The 52-week low share price for Imugene Ltd (IMU:ASX)? is AU$0.04.
Imugene Ltd (IMU:ASX) does not pay a dividend.
Imugene Ltd (IMU:ASX) does not pay a dividend.
Imugene Ltd (IMU:ASX) has a franking level of 0%.
Imugene Ltd (IMU:ASX) is classified in the Healthcare.
The current P/E ratio for Imugene Ltd (IMU:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.